Trial Profile

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darovasertib (Primary)
Indications Uveal melanoma
Focus Adverse reactions; Proof of concept
Acronyms NADOM
Sponsors IDEAYA Biosciences

Most Recent Events

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
03 Jun 2024 Results published in the IDEAYA Biosciences Media Release.
07 May 2024 According to an IDEAYA Biosciences media release, the company announced interim results from the trial have been accepted for an oral presentation at the upcoming 2024 ASCO annual meeting on June 3, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com